You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK):傳奇生物與楊森簽訂臨時產品供應協議

格隆匯3月8日丨金斯瑞生物科技(01548.HK)發佈公吿,公司非全資附屬公司傳奇生物(其股份以美國存托股份形式於美國納斯達克全球精選市場上市)已向美國證券交易委員會提交 6-K表格,宣佈關於Legend Biotech USA Inc.(“傳奇美國”)與Janssen Biotech, Inc.於2017年12月21簽署的合作與許可協議,傳奇美國與Janssen Pharmaceuticals, Inc.(“楊森”)已於2022年2月28日簽訂臨時產品供應協議,根據該協議,傳奇美國將向楊森供應ciltacabtagene autoleucel (cilta-cel),用於全球臨牀和商業用途(除大中華區)。

根據協議,楊森根據生產和供應此產品所需的總成本向傳奇美國支付所供應產品的轉讓價格。然而,產品的商業供應和臨牀供應成本最終由傳奇美國和楊森根據合作與許可協議作為“准許費用”和“開發成本”分別進行平均分攤。該協議將持續生效,直至(i)歐洲藥品管理局授予cilta-cel上市許可後的第45天和(ii)根據合作與許可協議建立的聯合制造委員會(JMC)確定的日期(二者中較早者)。如果合作與許可協議到期或終止,該協議也將終止。傳奇生物預計將與楊森簽訂產品供應協議,以取代該協議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account